|
|
||||||||
Research Service and Nuclear Medicine Service, V.A. Medical Center, Sepulveda
Department of Surgery, University of California, Los Angeles, California
Correspondence: For reprints contact: Marvin B. Cohen, Nuclear Medicine Service, V.A. Medical Center, Sepulveda, CA 91343.
ABSTRACT
Iodoamphetamine (IMP) was shown by in vitro assay to have a high uptake by human melanotic melanoma cells, as compared to amelanotic melanoma cells. Eleven patients with proven malignant melanoma (MM) and 3 normal subjects were imaged at 24 hr and 1624 hr after the i.v. injection 5 mCi (185 MBq) of [123I]IMP. One patient had a recurrent tumor that was subsequently shown to be squamous cell carcinoma. The index lesion was not visualized in the three patients with amelanotic melanomas. The index lesion/lesions were visualized in six of the seven other patients, except for 4/16 nodules in one patient. The seventh patient had a large, necrotic melanotic tumor that was not visualized, but an unsuspected lesion in the iliac nodes was detected. Multiple unsuspected lesions were detected in a second patient. While many lesions were seen at 24 hr, all lesions (other than a patient with small bowel disease) were seen best at 1624 hr. No eye uptake was observed in any patient or control subject. Testicular uptake was seen in all males at 1624 hr. Iodine-123 IMP appears to be a useful agent for the detection and follow-up of patients with melanotic MM.
This article has been cited by other articles:
![]() |
K. Kato, T. Kubota, M. Ikeda, M. Tadokoro, S. Abe, S. Nakano, M. Nishino, H. Kobayashi, and T. Ishigaki Low Efficacy of 18F-FDG PET for Detection of Uveal Malignant Melanoma Compared with 123I-IMP SPECT J. Nucl. Med., March 1, 2006; 47(3): 404 - 409. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |